Loading clinical trials...
Loading clinical trials...
A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Subjects With Binge Drinking/ Alcohol Use Disorder (AUD)
Conditions
Interventions
CMND-100
Locations
3
United States
Connecticut Mental Health Center
New Haven, Connecticut, United States
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States
The Sophie and Abram Stuchynski Israeli Alzheimer Medical Center
Ramat Gan, Israel
Start Date
March 31, 2025
Primary Completion Date
May 1, 2025
Completion Date
October 1, 2025
Last Updated
February 14, 2025
NCT05855668
NCT07071779
NCT07413458
NCT06793488
NCT06939088
NCT06648642
Lead Sponsor
Clearmind Medicine Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions